Adial Pharmaceuticals Inc... (ADIL)
NASDAQ: ADIL
· Real-Time Price · USD
0.65
-0.13 (-16.67%)
At close: May 02, 2025, 3:59 PM
0.69
5.85%
After-hours: May 02, 2025, 05:56 PM EDT
-16.67% (1D)
| Bid | 0.66 |
| Market Cap | 4.27M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -13.2M |
| EPS (ttm) | -2.72 |
| PE Ratio (ttm) | -0.24 |
| Forward PE | -0.52 |
| Analyst | Buy |
| Ask | 0.69 |
| Volume | 23,537,889 |
| Avg. Volume (20D) | 877,116 |
| Open | 0.90 |
| Previous Close | 0.78 |
| Day's Range | 0.63 - 1.21 |
| 52-Week Range | 0.58 - 3.00 |
| Beta | 1.26 |
About ADIL
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 27, 2018
Employees 5
Stock Exchange NASDAQ
Ticker Symbol ADIL
Website https://www.adialpharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ADIL stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 1130.77% from the latest price.
Stock Forecasts2 months ago
+20.64%
Adial Pharmaceuticals shares are trading higher af...
Unlock content with
Pro Subscription
5 months ago
+15.04%
Adial Pharmaceuticals shares are trading higher after the company announced results from its AD04-103 pharmacokinetics study for AD04, aimed at treating alcohol use disorder.
